| Literature DB >> 33361589 |
Julian Hirt1,2, Nicola Ballhausen3,4, Alexandra Hering4,5, Matthias Kliegel4,5,6, Thomas Beer1, Gabriele Meyer2.
Abstract
BACKGROUND: Using non-pharmacological interventions is a current approach in dementia care to manage responsive behaviors, to maintain functional capacity, and to reduce emotional stress. Novel technologies such as social robot interventions might be useful to engage people with dementia in activities and interactions as well as to improve their cognitive, emotional, and physical status.Entities:
Keywords: Dementia; robotics; systematic review; technology
Year: 2021 PMID: 33361589 PMCID: PMC7902949 DOI: 10.3233/JAD-200347
Source DB: PubMed Journal: J Alzheimers Dis ISSN: 1387-2877 Impact factor: 4.472
Fig. 1Search and study selection process.
Description of the different types of social robots used in the included studies
| Type | Description |
| CuDDler | Pet robot, robotic teddy bear, moves its neck, arms, eyelids, limbs and vocally interacts with a growl, developed in Singapore [ |
| NAO | Humanoid robot, can use oral language (phrases previously recorded) and move like a human, developed in France [ |
| PARO | Pet robot, animal-shaped robot, does not use oral language but sounds and moves like an animal/baby seal, developed in Japan [ |
| Telenoid | Telepresence robot, alien-shaped robot, transmits voices, mimics, and head motions using an internet connection, developed in Japan [ |
| JustoCat | Pet robot, robotic cat developed based on PARO, purrs, meows, and breaths, developed in Sweden [ |
Reporting assessment of included studies by means of CReDECI 2 (n = 16)
| Description of . . . | Demange | Moyle | Liang | Moyle | Petersen | Rouaix | Jøranson | Kuwamura | Moyle | Bemelmans | Gustafsson | Jøranson | Valenti | Valenti | Moyle | Sant’Anna |
| et al.,2018 [ | et al.,2018 [ | et al.,2017 [ | et al.,2017 [ | et al.,2017 [ | et al.,2017 [ | et al.,2016 [ | et al.,2016 [ | et al.,2016 [ | et al.,2015 [ | et al.,2015 [ | et al.,2015 [ | Soler et al.,2015 [ | Soler et al.,2015 [ | et al.,2013 [ | et al.,2012 [ | |
| First stage - Development | ||||||||||||||||
| . . . the intervention’s underlying theoretical basis | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| . . . all intervention components | N | N | N | N | N | N | N | N | N | N | N | N | N | N | Y | N |
| . . . any intended interactions between different components | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| . . . the context’s characteristics in intervention modelling | N | N | Y | N | N | N | N | N | N | N | N | N | N | N | N | Y |
| Second stage - Feasibility and piloting | ||||||||||||||||
| . . . the pilot-test and its impact on the definite intervention | Y | Y | Y | Y | N | Y | N | Y | Y | Y | Y | N | Y | Y | Y | Y |
| Third stage –Evaluation | ||||||||||||||||
| . . . the control condition (comparator) and reasons for the selection | NA | N | NA | N | N | NA | N | NA | NA | N | NA | N | NA | NA | NA | NA |
| . . . the strategy for delivering the intervention | NA | Y | NA | Y | Y | NA | Y | NA | NA | Y | NA | Y | NA | NA | NA | NA |
| . . . all materials or tools used for the delivery of the intervention | NA | N | NA | N | N | NA | N | NA | NA | N | NA | N | NA | NA | NA | NA |
| . . . fidelity of the delivery process compared to the study protocol | NA | N | NA | N | N | NA | N | NA | NA | N | NA | N | NA | NA | NA | NA |
| . . . a process evaluation and its underlying theoretical basis | NA | Y | NA | Y | N | NA | N | NA | NA | N | NA | N | NA | NA | NA | NA |
| . . . internal facilitators and barriers potentially influencing the delivery of the intervention as revealed by the process evaluation | NA | N | NA | N | N | NA | N | NA | NA | N | NA | N | NA | NA | NA | NA |
| . . . external conditions or factors occurring during the study which might have influenced the delivery of the intervention | NA | N | NA | N | N | NA | N | NA | NA | Y | NA | N | NA | NA | NA | NA |
| . . . costs for the delivery of the intervention | N | Y | N | Y | N | N | N | N | N | N | N | N | N | N | Y | N |
N, no, not reported; NA, not applicable; Y, yes, reported.
Reporting assessment of included studies by means of TIDieR (n = 16)
| Demange | Moyle | Liang | Moyle | Petersen | Rouaix | Jøranson | Kuwamura | Moyle | Bemelmans | Gustafsson | Jøranson | Valenti | Valenti | Moyle | Sant’Anna | |
| et al.,2018 [ | et al.,2018 [ | et al.,2017 [ | et al.,2017 [ | et al.,2017 [ | et al.,2017 [ | et al.,2016 [ | et al.,2016 [ | et al.,2016 [ | et al.,2015 [ | et al.,2015 [ | et al.,2015 [ | Soler et al.,2015 [ | Soler et al.,2015 [ | et al.,2013 [ | et al.,2012 [ | |
| Brief name | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Why | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N |
| What: Materials | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| What: Procedures | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Who provided | N | N | N | N | N | N | N | Y | Y | N | N | N | Y | Y | Y | N |
| How | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Where | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | N | Y | N | N | N | Y |
| When and how much | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y |
| Tailoring | Y | Y | Y | Y | - | Y | NA | Y | Y | Y | Y | - | Y | Y | NA | - |
| Modifications | - | NA | - | NA | - | NA | NA | - | - | - | - | - | NA | NA | - | - |
| How well (planned) | - | - | - | - | - | Y | - | - | - | - | Y | - | - | - | Y | - |
| How well (actual) | - | - | - | Y | - | Y | Y | - | - | - | - | Y | - | - | - | - |
NA, not applicable because the intervention was not tailored or modified; N, no, not reported; Y, yes, reported; -, unclear whether it was conducted.
Reporting assessment on ethical issues in the included studies (n = 16)
| Was ethical approval obtained? | Was informed consent obtained? | Who provided informed consent? | How was informed consent obtained regarding procedures? | Was ongoing consent/assent obtained? | How was ongoing consent/assent obtained regarding procedures? | Were ethical issues discussed by the authors? procedures? | |
| Demange et al., 2018 [ | ? | Y | L, P | ? | Y | Y | N |
| Moyle et al., 2018 [ | Y | Y | F, P | ? | Y | ? | N |
| Liang et al., 2018 [ | Y | Y | F | ? | ? | ? | N |
| Moyle et al., 2017 [ | Y | Y | F, P | ? | Y | ? | N |
| Petersen et al., 2017 [ | Y | Y | F, P | ? | ? | ? | N |
| Rouaix et al., 2017 [ | ? | Y | P | ? | ? | ? | N |
| Jøranson et al., 2016 [ | Y | Y | F, P | ? | ? | ? | N |
| Kuwamura et al., 2016 [ | Y | Y | F, H | ? | ? | ? | N |
| Moyle et al., 2016 [ | Y | Y | L | ? | Y | ? | N |
| Bemelmans et al., 2015 [ | Y | Y | L | ? | Y | ? | N |
| Gustafsson et al., 2015 [ | Y | Y | F, P | ? | ? | ? | N |
| Jøranson et al., 2015 [ | Y | Y | F, P | ? | ? | ? | N |
| Valenti Soler et al., 2015 [ | Y | Y | F, L, P | ? | ? | ? | N |
| Nursing home | |||||||
| Valenti Soler et al., 2015 [ | Y | Y | F, L, P | ? | ? | ? | N |
| Day care center | |||||||
| Moyle et al., 2013 [ | Y | Y | F, L | ? | ? | ? | N |
| Sant’Anna et al., 2012 [ | ? | Y | F | ? | ? | ? | N |
?, no (detailed) information; H, health professional; N, no, not reported; F, family member, next-of-kin, informal caregiver; L, legal representative, guardian; P, person with dementia; Y, yes, reported.
Critical appraisal using the JBI tool for experimental trials (n = 8)
| Moyle et al., | Liang et al., | Moyle et al., | Petersen et al., | Jøranson et al., | Jøranson et al., | Valenti Soler et al., | Moyle et al., | |
| 2018 [ | 2017 [ | 2017 [ | 2017 [ | 2016 [ | 2015 [ | 2015 [ | 2013 [ | |
| True randomisation | Y | Y | Y | Y | U | U | Y | Y |
| Concealed allocation | Y | Y | Y | U | Y | Y | U | Y |
| Groups similar at baseline | Y | Y | Y | Y | Y | Y | Y | Y |
| Participants blinded | NA | NA | NA | NA | NA | NA | NA | NA |
| Deliverers of treatment blinded | NA | NA | NA | NA | NA | NA | NA | NA |
| Outcome assessors blinded | Y | U | Y | U | N | N | Y | Y |
| Groups treated identically | Y | Y | Y | Y | Y | Y | Y | Y |
| Complete follow-up | Y | U | Y | U | Y | Y | Y | Y |
| Intention to treat analysis | Y | U | Y | U | Y | Y | Y | Y |
| Outcome measurement identically for groups | Y | Y | Y | Y | Y | Y | Y | Y |
| Reliable outcome measurement | Y | Y | Y | Y | Y | Y | Y | Y |
| Appropriate statistical analysis | Y | Y | Y | Y | Y | Y | Y | Y |
| Appropriate trial design | Y | Y | Y | Y | Y | Y | Y | Y |
| Overall Y (%) | 85 | 62 | 85 | 54 | 69 | 69 | 77 | 85 |
NA, not applicable; N, no; U, unclear; Y, yes.
Critical appraisal using the JBI tool for quasi-experimental trials (n = 4)
| Demange et al., | Rouaix et al., | Bemelmans et al., | Valenti Soler et al., | |
| 2018 [ | 2017 [ | 2015 [ | 2015 [ | |
| Similar participants | Y | Y | Y | Y |
| Similar treatment | Y | Y | Y | Y |
| Control group | N | N | Y | N |
| Outcome measurement pre and post intervention | Y | Y | Y | Y |
| Complete follow-up | Y | U | Y | U |
| Similar outcome measurement | Y | Y | Y | Y |
| Reliable outcome measurement | Y | Y | U | Y |
| Appropriate statistical analysis | Y | Y | Y | Y |
| Overall Y (%) | 88 | 75 | 88 | 75 |
N, no; U, unclear; Y, yes.
Critical appraisal using the JBI tool for pre-post case studies (n = 4)
| Kuwamura | Moyle | Gustafsson | Sant’Anna | |
| et al., 2016 [ | et al., 2016 [ | et al., 2015 [ | et al., 2012 [ | |
| Clear reporting of demographics of participants | Y | Y | N | N |
| Clear reporting of clinical information of participants | Y | Y | N | N |
| Outcomes clearly reported | Y | Y | Y | Y |
| Clear reporting of setting | Y | Y | Y | N |
| Overall Y (%) | 100 | 100 | 50 | 25 |
N, no; Y, yes.
Fig. 2Harvest plot illustrating the benefit and internal validity of included studies (n = 16) clustered by type of social robot intervention.